Literature DB >> 2389702

Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.

W B Kannel1, R B D'Agostino, P W Wilson, A J Belanger, D R Gagnon.   

Abstract

The influence of fibrinogen on the risk of cardiovascular disease is examined over 16 years of follow-up in 1314 subjects who were initially free of cardiovascular disease in the Framingham Study. Of these subjects, 46 men and 43 women developed diabetes, and 56 men and 53 women had blood sugar levels that exceeded 120 mg/dl. Diabetes predisposed subjects to all of the 408 major cardiovascular disease outcomes. Diabetics had higher levels of fibrinogen, hypertension, hypertriglyceridemia, and obesity, but lower HDL cholesterol values. The influence of diabetes on cardiovascular disease was greatly dependent on these coexistent risk factors, but there was a substantial independent effect of glucose intolerance when all the standard risk factors had been taken into account. There was a rise in fibrinogen values throughout the range of blood sugar levels, which suggests a thrombogenic explanation for the unique diabetic effect. However, multivariate analysis indicates no further reduction in diabetic cardiovascular risk ratios after adjustment for fibrinogen; thus, there is a residual effect for glucose intolerance after all of the standard risk factors and fibrinogen have been taken into account.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2389702     DOI: 10.1016/0002-8703(90)90026-t

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  56 in total

Review 1.  Pharmacological treatment of patients with peripheral arterial disease.

Authors:  Chin K Kim; Carsten M Schmalfuss; Richard S Schofield; David S Sheps
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Incidence and risk factors for cardiovascular disease in African Americans with diabetes: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Ayokanmi Adeniyi; Aaron R Folsom; Frederick L Brancati; Moise Desvorieux; James S Pankow; Herman Taylor
Journal:  J Natl Med Assoc       Date:  2002-12       Impact factor: 1.798

3.  Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease.

Authors:  M Donatelli; E Hoffmann; I Colletti; G Andolina; V Russo; M L Bucalo; T M Valenti; V Compagno; M G Cataldo; M L Morici
Journal:  Acta Diabetol       Date:  1996-09       Impact factor: 4.280

4.  Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study.

Authors:  H Hämäläinen; T Rönnemaa; A Virtanen; J Lindström; J G Eriksson; T T Valle; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Rastas; S Aunola; M Uusitupa; J Tuomilehto
Journal:  Diabetologia       Date:  2005-10-05       Impact factor: 10.122

5.  Application of HELP in nonarteritic anterior ischemic optic neuropathy: a prospective, randomized, controlled study.

Authors:  A Haas; M Walzl; F Jesenik; B Walzl; A Berghold; J Berglöff; B Feigl; J Faulborn
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-01       Impact factor: 3.117

6.  Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study.

Authors:  Chirantan Banerjee; Yeseon P Moon; Myunghee C Paik; Tatjana Rundek; Consuelo Mora-McLaughlin; Julio R Vieira; Ralph L Sacco; Mitchell S V Elkind
Journal:  Stroke       Date:  2012-03-01       Impact factor: 7.914

Review 7.  Cardiovascular disease: much more aggressive in patients with type 2 diabetes.

Authors:  Elaine Chiquette; Robert Chilton
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

8.  Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study.

Authors:  A J Lee; G D Lowe; M Woodward; H Tunstall-Pedoe
Journal:  Br Heart J       Date:  1993-04

9.  Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome.

Authors:  Daad Hassan Akbar
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

10.  Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study (PCS).

Authors:  S S Soedamah-Muthu; N Chaturvedi; J C Pickup; J H Fuller
Journal:  Diabetologia       Date:  2008-01-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.